Vitamin D Insufficiency in Infancy Not Linked to Food Allergy

Share this content:
Vitamin D Insufficiency in Infancy Not Linked to Food Allergy
Vitamin D Insufficiency in Infancy Not Linked to Food Allergy

THURSDAY, Jan. 5, 2017 (HealthDay News) -- Vitamin D insufficiency (VDI) at birth or age 6 months is not associated with food allergy at 1 year, according to a study published online Jan. 2 in Allergy.

John Molloy, M.B.Bao.Bch., from Deakin University in Waurn Ponds, Australia, and colleagues conducted a prospective investigation of the correlation between VDI during infancy and challenge-proven food allergy at 1 year of age. The authors used a case-cohort design in a birth cohort with 1,074 infants to compare 25-hydroxyvitamin-D3 levels among infants with food allergy versus a random subcohort of 274 infants.

The researchers found that within the random subcohort, VDI was present in 45 and 24 percent of newborns and infants aged 6 months, respectively. At 1 year, the prevalence of food allergy was 7.7 percent, and 6.5 percent were egg allergic. There was no correlation between VDI at birth or 6 months and food allergy at age 1 year (adjusted risk ratios, 1.25 [95 percent confidence interval, 0.70 to 2.22] and 0.93 [95 percent confidence interval, 0.41 to 2.14], respectively).

"There was no evidence that VDI during the first six months of infancy is a risk factor for food allergy at 1 year of age," the authors write. "These findings primarily relate to egg allergy and larger studies are required."

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Single-Payer Health System Bill Moves Forward in California

Single-Payer Health System Bill Moves Forward in California

Not yet clear where money for the single-payer system would come from

Regorafenib Approved for Hepatocellular Carcinoma

Regorafenib Approved for Hepatocellular Carcinoma

It is the first approved treatment for HCC in almost a decade

Three Anti-VEGF Treatments Effective for Diabetic Retinopathy

Three Anti-VEGF Treatments Effective for Diabetic Retinopathy

Rates of worsening low in patients receiving aflibercept, bevacizumab, or ranibizumab

is free, fast, and customized just for you!

Already a member?

Sign In Now »